Protocol MK-5475-007: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension
Primary Objective
Phase 2 cohort: To evaluate the effect of MK-4575 versus placebo on pulmonary vascular resistance from baseline to week 12. Phase 3 Cohort: To evaluate the effects of MK-5475 versus placebo on 6 minute walk test distances from baseline to week 12.
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
David Badesch, MD
Study ID
Protocol Number: 21-2564
More information available at ClinicalTrials.gov: NCT04732221
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers